Nuclear Theranostics in Turkey

  • Murat Fani BozkurtEmail author


Nuclear theranostics functions as a bridge which connects targeted diagnosis to targeted therapy, just like Turkey functions as a geographical bridge which connects Asia to Europe. This unique geographical site of the country plays an important role with regard to introduction of novel scientific and technologic improvements, which originate from one continent to another, in the era of accelerated information. The first nuclear medicine practice in Turkey started in the beginning of 1950s with the first radioiodine treatment, which actually was a debut for nuclear theranostics in Turkey, years before many other countries in the world. For the time being, along with radioiodine treatment, many other theranostic applications such as I-131 MIBG treatment, Lu-177/Y-90 DOTA peptide treatment, Lu-177 PSMA treatment, Y-90 microsphere treatment, and bone palliative treatment are being performed in many centers countrywide. As science and technology improves, novel theranostic applications are eagerly awaited to be introduced in near future. This paper summarizes the story of nuclear theranostics in Turkey and aims to give an overview on the current status of theranostic applications in Turkey.


Theranostics Nuclear medicine Turkey I-131 I-131 MIBG Radionuclide therapy 



This paper would have never been possible without the visionary support of Executive Board members of Turkish Society of Nuclear Medicine Prof Gamze CAPA KAYA M. D. (President), Prof Dogangun YUKSEL M.D. (Vice-President), Prof Tevfik Fikret CERMIK M.D. (Secretary), Prof Elvan SAYIT BILGIN, Prof Gulin UCMAK, M. D. (member), and Prof Hakan DEMIR (member) as well as the valuable data support from the industrial partners in the field, in particular “Monrol-Eczacibasi” and “BTG” companies.

Compliance with Ethical Standards

Conflict of Interest

Murat Fani BOZKURT declares that he has no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by the author.

Informed Consent

For this type of study, formal consent is not required.


  1. 1.
    Bozkurt MF, Ozcan Z. The evolving role of nuclear medicine and molecular imaging: theranostics and personalized therapeutic applications. Mol Imaging Radionucl Ther. 2018;27:1–2.CrossRefGoogle Scholar
  2. 2.
    Bozkurt MF, Cermik TF, Sari O, Capa Kaya G, Sayit Bilgin G, Gungor F, et al. Turkiye’de Nukleer Tip:Tarihsel Yolculugumuzda Donum Noktalari. Nukleer Tip Seminerleri: Nuclear Medicine Seminars. 2015;1:1–3.Google Scholar
  3. 3.
    Ozcan Z, Bozkurt MF, Erbas B, Durak H. Nuclear medicine training and practice in Turkey. Eur J Nucl Med Mol Imaging. 2017;44:903–8.CrossRefGoogle Scholar
  4. 4.
    Official website for the Turkish Atomic Energy Authority: Accessed 11 Nov 2018.

Copyright information

© Korean Society of Nuclear Medicine 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations